Mixed fortunes as good news follows bad on the rollout of Covid vaccines

A week of distress over the halving of AstraZeneca stocks ended on a brighter note as pharma firms rolled up their sleeves to help in the rollout and new vaccines look set to take up some of the slack

31st January, 2021
Mixed fortunes as good news follows bad on the rollout of Covid vaccines
Operators work on the pre-filled syringes assembly line at AstraZeneca’s new biologics factory in Sodertalje, Sweden Picture: Bloomberg

At the end of a difficult week for Europe’s vaccination programme, there was relief in the Department of Health as the AstraZeneca vaccine was approved for all adult age groups by the European Medicines Agency (EMA).

Speaking to the Business Post last Friday, Stephen Donnelly welcomed the approval, but cautioned that lower production from AstraZeneca’s European factories would mean the previously publicised target of vaccinating 700,000 people by the end of March would...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month, €19.99 Monthly thereafter

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Related Stories

Homeless charity’s frontline staff have yet to get vaccines

Analysis: Vaccination effect is evident among older age groups

Government rules out foreign holidays in June

Government should begin delayed dosing programme this week, O‘Neill says